Core Viewpoint - Titan Technology's stock has experienced fluctuations, with a year-to-date increase of 23.83% but a recent decline over the past 20 and 60 days, indicating potential volatility in its market performance [1]. Financial Performance - For the period from January to September 2025, Titan Technology reported a revenue of 1.848 billion yuan, representing a year-on-year decrease of 13.06%. However, the net profit attributable to shareholders increased by 15.04% to 11.1678 million yuan [2]. - Cumulative cash dividends since the company's A-share listing amount to 86.6205 million yuan, with 40.1089 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, Titan Technology had 9,293 shareholders, an increase of 20.41% from the previous period. The average number of circulating shares per shareholder decreased by 16.95% to 17,694 shares [2]. Business Overview - Titan Technology, established on October 18, 2007, and listed on October 30, 2020, is based in Shanghai and specializes in providing integrated technical solutions for scientific services, including research reagents, biological consumables, analytical consumables, laboratory instruments, and specialized chemicals. The main revenue sources are research reagents (42.70%), research instruments and consumables (28.42%), and specialized chemicals (26.48%) [1].

Company Overview - Titan Technology Co., Ltd. is located at 89 Shilong Road, Xuhui District, Shanghai, established on October 18, 2007, and listed on October 30, 2020 [1] - The company provides integrated technical solutions for scientific services, including research reagents, biological consumables, analytical consumables, laboratory instruments, smart laboratory equipment, research information technology, specialty chemicals, and related comprehensive technical services [1] Financial Performance - For the period from January to September 2025, Titan Technology achieved operating revenue of 1.848 billion yuan, a year-on-year decrease of 13.06% [2] - The net profit attributable to the parent company was 11.1678 million yuan, a year-on-year increase of 15.04% [2] - Cumulative cash dividends since the A-share listing amount to 86.6205 million yuan, with 40.1089 million yuan distributed over the past three years [3] Stock Performance - As of December 1, Titan Technology's stock price increased by 2.14%, reaching 23.40 yuan per share, with a total market capitalization of 3.848 billion yuan [1] - Year-to-date, the stock price has risen by 28.78%, with a 4.09% increase over the last five trading days, a 4.29% decrease over the last 20 days, and a 10.52% decrease over the last 60 days [1] - The stock has a turnover rate of 0.70%, with a trading volume of 26.5661 million yuan [1] Shareholder Information - As of September 30, the number of shareholders increased by 20.41% to 9,293, while the average circulating shares per person decreased by 16.95% to 17,694 shares [2] Business Segments - The main business revenue composition includes: research reagents (42.70%), research instruments and consumables (28.42%), specialty chemicals (26.48%), laboratory construction and research information technology (2.37%), and others (0.02%) [1]

Core Points - The stock price of Chuan Yi Co., Ltd. dropped by 2.04% on November 28, trading at 24.06 yuan per share with a market capitalization of 12.347 billion yuan [1] - The company has seen a year-to-date stock price increase of 14.71%, but a recent decline of 2.59% over the last five trading days [1] - Chuan Yi Co., Ltd. specializes in industrial automation control systems, with 86.81% of its revenue coming from industrial automation instruments and devices [1] Financial Performance - For the period from January to September 2025, Chuan Yi Co., Ltd. reported a revenue of 4.890 billion yuan, a year-on-year decrease of 13.02%, and a net profit attributable to shareholders of 462 million yuan, down 17.28% year-on-year [2] - Cumulative cash dividends since the company's A-share listing amount to 1.527 billion yuan, with 828 million yuan distributed over the last three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 2.54% to 18,600, while the average number of tradable shares per person increased by 2.60% to 27,482 shares [2] - Hong Kong Central Clearing Limited is the fifth-largest shareholder, holding 12.0266 million shares, an increase of 8.5233 million shares from the previous period [3]

Core Viewpoint - The stock of Chuan Yi Co., Ltd. has experienced fluctuations, with a recent decline of 2.01% and a year-to-date increase of 21.14%, indicating volatility in the market performance of the company [1]. Financial Performance - For the period from January to September 2025, Chuan Yi Co., Ltd. reported a revenue of 4.89 billion yuan, a year-on-year decrease of 13.02%, and a net profit attributable to shareholders of 462 million yuan, down 17.28% compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 1.527 billion yuan, with 828 million yuan distributed over the last three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Chuan Yi Co., Ltd. was 18,600, a decrease of 2.54% from the previous period, while the average circulating shares per person increased by 2.60% to 27,482 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 12.0266 million shares, an increase of 8.5233 million shares from the previous period [3]. Market Activity - The stock price of Chuan Yi Co., Ltd. is currently at 25.41 yuan per share, with a market capitalization of 13.04 billion yuan. The trading volume shows a net outflow of 17.8569 million yuan from main funds [1]. - The company operates primarily in the industrial automation sector, with 86.81% of its revenue coming from industrial automation instruments and devices [1].

Core Viewpoint - RunDa Medical's stock has shown mixed performance in recent trading sessions, with a slight increase in price but a significant decline in revenue and profit year-over-year [1][2]. Financial Performance - As of September 30, 2025, RunDa Medical reported a revenue of 5.268 billion yuan, representing a year-over-year decrease of 14.70% [2]. - The company experienced a net profit loss of 163 million yuan, a substantial decline of 422.64% compared to the previous year [2]. Stock Performance - On November 25, 2025, RunDa Medical's stock price increased by 2.11%, reaching 16.45 yuan per share, with a total market capitalization of 9.93 billion yuan [1]. - Year-to-date, the stock has risen by 3.46%, with a 3.01% increase over the last five trading days and a 6.61% increase over the last 20 days, while it has decreased by 12.96% over the last 60 days [1]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased to 64,800, a reduction of 1.05% from the previous period [2]. - The average number of circulating shares per shareholder increased by 1.06% to 9,317 shares [2]. Dividend Information - RunDa Medical has distributed a total of 373 million yuan in dividends since its A-share listing, with 165 million yuan distributed over the past three years [3]. Institutional Holdings - Among the top ten circulating shareholders, the Southern CSI 1000 ETF holds 4.4119 million shares, a decrease of 48,700 shares from the previous period [3]. - Hong Kong Central Clearing Limited is a new entrant among the top ten shareholders, holding 4.1516 million shares [3].

Company Overview - Titan Technology Co., Ltd. is located at 89 Shilong Road, Xuhui District, Shanghai, established on October 18, 2007, and listed on October 30, 2020 [1] - The company provides integrated technical solutions for scientific services, including research reagents, biological consumables, analytical consumables, laboratory instruments, smart laboratory equipment, research information technology, specialty chemicals, and related comprehensive technical services [1] - The revenue composition of Titan Technology is as follows: research reagents 42.70%, research instruments and consumables 28.42%, specialty chemicals 26.48%, laboratory construction and research information technology 2.37%, and others 0.02% [1] Financial Performance - As of September 30, Titan Technology reported a total revenue of 1.848 billion yuan for the period from January to September 2025, a year-on-year decrease of 13.06% [2] - The net profit attributable to the parent company was 11.1678 million yuan, reflecting a year-on-year increase of 15.04% [2] - Cumulative cash dividends since the A-share listing amount to 86.6205 million yuan, with 40.1089 million yuan distributed over the past three years [3] Stock Performance - On November 20, Titan Technology's stock price decreased by 2.01%, trading at 22.92 yuan per share, with a total market capitalization of 3.769 billion yuan [1] - The stock has seen a year-to-date increase of 26.14%, but has declined by 7.99% over the last five trading days, 8.14% over the last 20 days, and 18.26% over the last 60 days [1] - As of the latest data, the number of shareholders is 9,293, an increase of 20.41% from the previous period, while the average circulating shares per person decreased by 16.95% to 17,694 shares [2] Market Activity - The net outflow of main funds was 4.5418 million yuan, with large orders buying 4.3981 million yuan (16.17% of total) and selling 8.9399 million yuan (32.87% of total) [1] - Titan Technology is categorized under the basic chemicals industry, specifically in the chemical products sector, and is associated with concepts such as buybacks, margin financing, pension concepts, scientific instruments, and electronic chemicals [1]

Core Viewpoint - Dian Diagnostics has shown a significant stock price increase of 48.75% year-to-date, despite a recent decline in revenue and net profit [1][2]. Group 1: Stock Performance - On November 18, Dian Diagnostics' stock rose by 2.23%, reaching 16.52 CNY per share, with a trading volume of 1.17 billion CNY and a turnover rate of 1.43%, resulting in a total market capitalization of 103.25 billion CNY [1]. - The stock has experienced a slight increase of 0.06% over the last five trading days, a 7.97% increase over the last 20 days, and a minor decline of 0.12% over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on February 17 [1]. Group 2: Financial Performance - For the period from January to September 2025, Dian Diagnostics reported a revenue of 75.66 billion CNY, reflecting a year-on-year decrease of 18.28%, while the net profit attributable to shareholders was 56.70 million CNY, down 56.67% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 10.99 billion CNY in dividends, with 7.12 billion CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Dian Diagnostics was 45,700, a decrease of 5.45% from the previous period, with an average of 10,974 shares held per shareholder, an increase of 5.76% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 10.56 million shares, a decrease of 4.23 million shares from the previous period [3].

Company Overview - Titan Technology Co., Ltd. is located at 89 Shilong Road, Xuhui District, Shanghai, established on October 18, 2007, and listed on October 30, 2020 [1] - The company provides integrated technical solutions for scientific services, including research reagents, biological consumables, analytical consumables, laboratory instruments, smart laboratory equipment, research information technology, specialty chemicals, and related comprehensive technical services [1] Financial Performance - For the period from January to September 2025, Titan Technology achieved operating revenue of 1.848 billion yuan, a year-on-year decrease of 13.06% [2] - The net profit attributable to the parent company was 11.1678 million yuan, representing a year-on-year increase of 15.04% [2] - Cumulative cash dividends since the A-share listing amount to 86.6205 million yuan, with 40.1089 million yuan distributed over the past three years [3] Stock Performance - As of November 12, Titan Technology's stock price decreased by 2.15%, trading at 24.13 yuan per share, with a total market capitalization of 3.968 billion yuan [1] - Year-to-date, the stock price has increased by 32.80%, with a slight increase of 0.54% over the last five trading days, but a decline of 0.33% over the last 20 days and 13.33% over the last 60 days [1] - The number of shareholders as of September 30 was 9,293, an increase of 20.41% from the previous period, while the average circulating shares per person decreased by 16.95% to 17,694 shares [2] Business Segmentation - The main business revenue composition includes: research reagents (42.70%), research instruments and consumables (28.42%), specialty chemicals (26.48%), laboratory construction and research information technology (2.37%), and others (0.02%) [1] - Titan Technology is classified under the Shenwan industry as basic chemicals - chemical products - other chemical products, and is associated with concepts such as share buybacks, margin financing, electronic chemicals, pension concepts, and scientific instruments [1]

Core Points - Aladdin's stock price increased by 2.07% on November 10, reaching 13.31 CNY per share, with a total market capitalization of 4.427 billion CNY [1] - The company reported a year-to-date stock price increase of 17.44%, with a recent 5-day increase of 3.26% and a 60-day decrease of 11.27% [1] - Aladdin's main business involves the research, production, and sales of reagents, with 96.96% of revenue coming from scientific reagents [1] Financial Performance - For the period from January to September 2025, Aladdin achieved operating revenue of 444 million CNY, representing a year-on-year growth of 17.59% [2] - The net profit attributable to the parent company was 57.76 million CNY, showing a year-on-year decrease of 20.41% [2] Shareholder Information - As of September 30, 2025, the number of Aladdin's shareholders decreased by 7.17% to 11,600, while the average circulating shares per person increased by 7.72% to 28,729 shares [2] - Since its A-share listing, Aladdin has distributed a total of 241 million CNY in dividends, with 150 million CNY distributed in the last three years [3] - Notably, some institutional investors exited the top ten circulating shareholders list as of September 30, 2025 [3]

Core Viewpoint - The launch of the first international academic journal in the field of high-end scientific instruments in China, titled "Advanced Scientific Instruments" (ASI), aims to address the publication challenges in this sector and establish a world-class platform for academic exchange [2][4]. Group 1: Journal Overview - The journal is hosted by China Science Publishing & Media Ltd. and aims to break the "research without platform" dilemma in high-end scientific instruments [2]. - ASI serves as a cross-disciplinary international exchange platform for research results in the fields of instruments, instrumentation, and measurement [4]. Group 2: Journal Sections - Section A focuses on the development of scientific instruments, covering innovative designs, methods, and theoretical aspects [5][6]. - Section B emphasizes new devices and technologies in photonics, lasers, and radar, including various types of spectroscopy and optical metrology [7][8]. - Section C highlights advancements in imaging and microscopy, including micro-nano metrology and real-time image analysis [9][10]. - Section D discusses advanced theories and applications in microelectronics, optoelectronics, and chip-based processes [11][12]. - Section E covers automation in smart instruments, quantum sensing, and various measurement techniques [13][14]. - Section F focuses on new data analysis tools and methods, including machine learning and signal processing [15][16]. Group 3: Industry Context - Currently, there are several related journals in China's scientific instrument industry, such as "Journal of Analytical Chemistry" and "Journal of Instrumentation" [17]. - The inclusion of scientific instruments in national strategic priorities may lead to the emergence of more related journals in the future, potentially influencing procurement decisions for end-users [17].